Biocartis - About the company
Biocartis is a public company based in Mechelen (Belgium), founded in 2007 by Philippe Renaud and Rudi Pauwels. It operates as a Developer of molecular assays for the detection of various diseases. Biocartis has raised $305M in funding from investors like Johnson & Johnson Innovation – JJDC, Aescap and Debiopharm. The company has 527 active competitors, including 144 funded and 118 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.
Company Details
Developer of molecular assays for the detection of various diseases. The company has developed its proprietary micro-technology platform that is based on integrated molecular and immunodiagnostics technology. It is used for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. It can also be used in the analysis of biomolecules associated with risk factors, early detection, staging, treatment selection, and monitoring of disease.
- Website
- www.biocartis.com/en-US
- Social
- Email ID
- *****@biocartis.com
- Phone Number
- +32 **********
- Registered Address
- Jersey City, New Jersey
Key Metrics
Founded Year
2007
Location
Mechelen, Belgium
Stage
Public
Total Funding
$305M in 18 rounds
Latest Funding Round
Investors
Ranked
19th among 527 active competitors
Annual Revenue
€10M - €50M as on Dec 31, 2024
Employee Count
309 as on May 31, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public
Legal entities associated with Biocartis
Biocartis is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Biocartis Nv CIN: 0827.475.227 , Belgium, Active | Jun 30, 2010 | €10M - €50M (As on Dec 31, 2024) | 407 (As on Dec 31, 2021) | - |
BIOCARTIS US, INC. CIN: 300975380 , United States, Active | Dec 26, 999 | - | 26 (As on Dec 31, 2024) | - |
Biocartis's IPO details
Biocartis got listed on Apr 27, 2015.
Click here to take a look at Biocartis's IPO in detail
Sign up to download Biocartis' company profile
Biocartis's funding and investors
Biocartis has raised a total funding of $305M over 18 rounds. Its first funding round was on Oct 15, 2009. Biocartis has 20 institutional investors.
Here is the list of recent funding rounds of Biocartis:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 01, 2022 | 8824719 | Post IPO | 5448856 | 9134407 | 3773157 | 6248520 |
May 11, 2021 | 5716840 | Grant (prize money) | 6618630 | 3075349 | 6199425 | |
Dec 07, 2020 | 6595022 | Post IPO | 2279619 | 1473904 | 4913089 | 8434294 |
Access funding benchmarks and valuations. Sign up today!View details of Biocartis's funding rounds and investors
Biocartis' founders and board of directors
Founder? Claim ProfileThe founders of Biocartis are Philippe Renaud and Rudi Pauwels.
Here are the details of Biocartis' key team members:
- Philippe Renaud: Co-Founder, Scientific Advisor of Biocartis and founder of 2 other companies, UniPix Lab and Volumina Medical.
- Rudi Pauwels: Founder of Biocartis.
- Herman Verrelst: CEO of Biocartis. They are also an angel investor in 2 startups.Contact Info: 1 email address
View details of Biocartis's Founder profiles and Board Members
Biocartis' employee count trend
Biocartis has 309 employees as of May 26. Here is Biocartis's employee count trend over the years:
Uncover Biocartis' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Biocartis's Competitors and alternates
Top competitors of Biocartis include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Biocartis, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
3rd | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 72/100 | |
4th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 71/100 | |
5th | Exact Sciences 1995, Madison (United States), Acquired | Provider of non-invasive molecular diagnostic testing solutions for cancer | - | 71/100 | |
6th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 70/100 | |
7th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 70/100 | ||
8th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
9th | Delfi Diagnostics 2019, Baltimore (United States), Series B | Provider of DNA sequencing for cancer detection | $332M | 68/100 | |
10th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
19th | Developer of molecular assays for the detection of various diseases | $305M | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Biocartis's competitors? Click here to see the top ones
Biocartis's Investments and acquisitions
Biocartis has acquired Pronota. Biocartis has not made any investments as of now.News related to Biocartis
Filter this listMedia has covered Biocartis for a total of 6 events in the last 1 year, 3 of them have been about partnerships and 1 about company updates.
•
•
•
•
Biocartis to Collaborate with Mayo Clinic on Breast Cancer Gene SignaturesGlobeNewswire•Jan 12, 2026•Mayo Clinic, Biocartis
•
•
Biocartis Welcomes Mike Kreitzinger as Senior Vice President of Global Business DevelopmentGlobeNewswire•Aug 18, 2025•Biocartis
•
BioCeltas-IA wins the Ministry's hackathon with an ecotourism proposalEl Referente•Jun 26, 2025•Biocartis
•
•
Biocartis' Idylla™ EGFR Mutation Test Receives IVDR Class C CDx CertificationGlobeNewswire•Jun 02, 2025•Biocartis
•
Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation AssayGlobeNewswire•Apr 02, 2025•Biocartis
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Biocartis
Explore our recently published companies
